Download curriculum vitae - Curie Manavata Cancer Centre

CURRICULUM VITAE
Name
Dr. Aditya Shirish Adhav
Address
Adhav Hospital,
Shivajinagar,
Opp. Inox theatre,
Nashik
422006
Phone number
0253-2414959
Mobile number
+919860376209
Email address
[email protected]
Date of birth
15/08/1987
Languages known
English, Marathi and Hindi
Educational details:Graduation
MBBS 2005-2010(NDMVPS
Medical College and Hospital,
Nashik)
Recognised by Medical
Council of India
Internship from Feb. 2010 to
Feb. 2011(NDMVPS Medical
College and Hospital, Nashik)
Post Graduation
PDVVPF’s Medical College,
Ahmednagar (1st June 201131stMay2014) under Maharashtra
University of Health Sciences.
Recognised by Medical Council of
India
Topic of Dissertation: - CLINICO-PATHOLOGICAL STUDY
OF NON NEOPLASTIC AND NEOPLASTIC LESIONS OF
BREAST WITH RADIOLOGICAL CORRELATION.
Senior resident
SMBT Hospital Nasik 18thDec 2014
to 28th Jan 2015
Bharati Vidyapeeth Deemed
University, Pune 2nd March
2015 to 30th June 2015.
Fellowship
Breast surgery at Manavata
Curie Cancer Centre, Nashik
affiliated with Maharashtra
University of Health Sciences
from 2nd July 2015 to 31st Aug
2016.
Achievements: Academics
Title
Year
M.S
Univers Institute
Marks
ity
MUHS, PDVVPF’s Medical 61%
Remarks
1st Attempt
General
Surgery
MBBS
Nashik
1st
2nd
3rd part
I
3rd part
II
College,
Ahmednagar
MUHS, NDMVPS Medical
Nashik College
MUHS, NDMVPS Medical
Nashik College
MUHS NDMVPS Medical
Nashik College
MUHS NDMVPS Medical
Nashik College
60%
64%
61%
62%
1st Attempt
1st Attempt
1st Attempt
1st Attempt
Paper Presentation
 Male Breast Lesions: A Scenario at our institute
Poster Presentation
 Benign Multicystic Peritoneal Mesothelioma
 Aesthetics in Breast Surgery
 Rare But There: Male Breast Cancer
Publications in Indexed Journal
 Benign Multicystic Peritoneal Mesothelioma
 Amyand’s Hernia A Rare Sliding Hernia
 Rare But There: Male Breast Cancer.
 Intracystic Papillary Carcinoma Of Breast: A Case Report.
 Anterior Mediastinal Mass: A Case Report Of Thymoma With
Myasthenia Gravis.
 Kikuchi Fujimoto Disease: A Rare Benign Disease.
Conferences Attended
1. Attended MASICON 2012 in Pune.
2. Poster presentation “Benign Multicystic Peritoneal
Mesothelioma” in Nashik MASICON 2013.
3. Attended ASICON at Ahmedabad in 2013.
4. Paper presentation “Male Breast Lesions: A Scenario at our
institute” at MASICON 2014.
5. Organised and attended Live Operative workshop and
Multidisciplinary CME on Breast Surgery at Curie Manavata
Cancer Centre Nashik October 2015.
6. Attended Current trends in Oncology Breast Chapter - 2016 at
Ruby Hall Clinic, Pune.
PRINCIPAL INVESTIGATOR IN
1) A Randomised double-blind study in two parts Part A –
Comparing two humanized monoclonal antibodies that target VEGF
in combination with mFOLFOX6 in patients with non-resectable
metastatic colorectal cancer (mCRC) and Part B – Comparing two
humanized monoclonal antibodies that target VEGF in combination
with pemetrexed and carboplatin in recurrent or advanced
nonsquemous non-small cell lung cancer (NSCLC).
2) A Randomized, Double-Blind, Multi- Centre, Parallel Group
Study Comparing Two Humanized Monoclonal Antibodies that
Target HER2 Receptors in Combination with Paclitaxel
Administered as First-Line Treatment in Patients with HER2 Positive Metastatic Breast Cancer.
3) A Randomized, Open Label, Two Period, Single Dose, Crossover,
Bioavailability Study Of Paclitaxel Injection Concentrate For Nano-
Dispersion (PICN) And Abraxane® In Subjects With Locally
Recurrent Or Metastatic Breast Cancer
SUB INVESTIGATOR IN
1) Prospective, multi-centric, randomized open-label, twoarm,
parallel group, active-control, comparative clinical study to evaluate
efficacy, safety and pharmacokinetics of R-TPR- 033 / Erbitux ® in
patients with recurrent locoregional or metastatic squamous cell
carcinoma of the head and neck.
2) A Prospective, Randomized, Multi- Centre Study to Compare the
Safety, Tolerability, and Efficacy Bevacizumab (Zydus Cadila) With
Bevacizumab (Avastin ®) in Non-Small Cell Lung Cancer
(NSCLC).
3) A Randomized,Double-blind,Placebo- controlled study to
Evaluate the Long- term Safety and Efficacy of Darbepoetin Alpha
Administered at 500mg once- Every-3- weeks in Anemic Subjects
with Advanced Stage Non-small cell Lung Cancer Receiving Multicycle Chemotherapy.
4) A Prospective, Comparative, Open Label, Randomized,
Multicentric, Phase III study to compare the safety and efficacy of
Bevacizumab of Inta Pharmaceuticals Limited against Avastin™ in
Patients with Unresectable or Metastatic Non-Squamous Non Small Cell Lung Cancer.